Abstract: In a method for tracking change data, data is changed in a field of a plurality of data in a database at a computer system, where the plurality of data is included within a base table of the database, the base table including an original state of the plurality of data, where changing the data changes a record header for the field within a change data table of the database, where the change data table includes changes made to the base table. A flag is created in the record header of the data signaling the change to the field within the change data table. Successive versions of the database are linked together such that a subscriber accessing the database can automatically view a current version of the database with the change by accessing the record header of the data and identifying the flag within the record header of the data.

Abstract: Structures for a non-volatile memory and methods of forming such structures. A gate electrode and a gate dielectric layer are formed over an active region with the gate dielectric layer between the gate electrode and the active region. A first doped region is formed in the active region, a second doped region is formed in the active region, and a source line is coupled to the second doped region. The first doped region is positioned in the active region at least in part beneath the gate dielectric layer, and the second doped region is positioned in the active region adjacent to the first doped region. The first doped region has a first conductivity type, and the second doped region has a second conductivity type opposite to the first conductivity type.

Abstract: Methods and reagents for determining treatment efficacy of a MALT1 inhibitor in a human subject are described. The method involves determining MALT1 regulated gene expression in stimulated PBMCs of a blood sample obtained from the subject. The method provides information for guiding treatment decisions for those subjects receiving a MALT1 inhibitor therapy, improves the accuracy of optimizing therapy, reduces toxicity, and/or monitors the efficacy of therapeutic treatment.

Abstract: Methods and reagents for determining treatment efficacy of a MALT1 inhibitor in a human subject are described. The method involves determining NF-?B nuclear translocation in stimulated PBMCs of a blood sample obtained from the subject. The method provides information for guiding treatment decisions for those subjects receiving a MALT1 inhibitor therapy, improves the accuracy of optimizing therapy, reduces toxicity, and/or monitors the efficacy of therapeutic treatment.

Abstract: A memory stores an environment file. A hardware processor receives a video file comprising a first frame and a second frame. The hardware processor determines a first object in the first frame and a first user action performed in the first frame. The hardware processor determines a second object in the second frame and a second user action performed in the second frame. The hardware processor determines a first keyword for the first user action and a second keyword for the second user action. The hardware processor determines, based on the first and second keywords, a first script and a second script from the environment file. The hardware processor then combines the first script and the second script to generate an automation script that, when executed, performs the first user action on the first object and the second user action on the second object.

Abstract: Combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, with a second anticancer agent are provided. Also provided are methods of treating cancers, and autoimmune disorders by administering combinations of Bruton's tyrosine kinase (Btk) inhibitors, e.g., 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, and second anticancer agents.

Abstract: Provided herein are methods of treating a B-cell malignancy, and gene mutations that can be used to identify subjects who will be responsive to treatment of a B-cell malignancy with a combination of ibrutinib and an anti-PD-1 antibody.

Abstract: A memory stores an environment file. A hardware processor receives a video file comprising a first frame and a second frame. The hardware processor determines a first object in the first frame and a first user action performed in the first frame. The hardware processor determines a second object in the second frame and a second user action performed in the second frame. The hardware processor determines a first keyword for the first user action and a second keyword for the second user action. The hardware processor determines, based on the first and second keywords, a first script and a second script from the environment file. The hardware processor then combines the first script and the second script to generate an automation script that, when executed, performs the first user action on the first object and the second user action on the second object.

Abstract: A method for enhanced oil recovery may comprise inputting into a computer system data related to properties of a hydrocarbon reservoir and depletion of the hydrocarbon reservoir; calculating, with the computer system, a current oil saturation and a current gas saturation of the hydrocarbon reservoir based on the data; determining, with the computer system, that the current reservoir pressure is less than a bubble point pressure based on the data; calculating, with the computer system, a time to repressure the hydrocarbon reservoir by waterflooding based on the data; comparing, with the computer system, the data related to properties of the hydrocarbon reservoir to oil recovery screening criteria; selecting a flooding technique from a plurality of flooding techniques, with the computer system, based on satisfying the oil recovery screening criteria with the data related to properties of the hydrocarbon reservoir; and flooding the hydrocarbon reservoir.

Abstract: Provided herein are methods of treating follicular lymphoma (FL) and gene mutations that can be used to predict a subject's nonresponsiveness to treatment of follicular lymphoma with ibrutinib.

Abstract: Methods and systems are disclosed for tracking change data in a database. A database, stored at a computer system, is accessed with a plurality of data written to fields in the database, wherein each data in the fields comprises a record header. Data is changed in at least one field of the plurality of data in the database via the computer system, wherein the changing the data changes the record header for the at least one field. A transaction identification (ID) is stored in the record header for each change to the at least one field. A flag is created in the record header signaling the change to the at least one field. Successive versions of the database are linked together such that a subscriber accessing the database can automatically view a current version of the database with the change by accessing the record header and identifying the flag.

Abstract: The current document is directed to a subsystem that is incorporated, in one implementation, within an automated application-release-management system. The subsystem to which the current document is directed determines, based on modifications to the source code for an application or another system that are submitted through a check-in process, a subset of tests within a large set of tests developed to test the application or system that invoke routines or other compilation units affected by the submitted source-code modifications. Only those tests that invoke routines and other compilation units affected by the source-code submissions need then be applied during testing and verification of the revised application or system.

Abstract: Methods and systems are disclosed for tracking change data in a database. A database, stored at a computer system, is accessed with a plurality of data written to fields in the database, wherein each data in the fields comprises a record header. Data is changed in at least one field of the plurality of data in the database via the computer system, wherein the changing the data changes the record header for the at least one field. A transaction identification (ID) is stored in the record header for each change to the at least one field. A flag is created in the record header signaling the change to the at least one field. Successive versions of the database are linked together such that a subscriber accessing the database can automatically view a current version of the database with the change by accessing the record header and identifying the flag.

Abstract: Techniques are disclosed for network-less provisioning of guest operating system and software. In one embodiment, a monitor process mounts a floppy image or ISO storing a deployment tool on a virtual CD/DVD device or virtual floppy device, respectively, of a VM and powers on the VM. The deployment tool is invoked upon powering on of the VM and requests that the monitor mount an OS ISO image on the virtual CD/DVD device. In response, the monitor mounts the OS ISO and transmits an acknowledgment to the deployment tool, which initiates OS installation from the OS ISO image. After the OS installation, the deployment tool transmits a further request that monitor clean-up resources consumed during the OS installation and reboots the VM, after which a similar process may be undertaken to install software for the VM.

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Abstract: Semiconductor memory devices and methods for writing data in memory cells are provided. An exemplary method for writing data in a memory cell includes providing the memory cell with a first pull-up transistor, a first power supply line coupled to the first pull-up transistor, a second pull-up transistor, and a second power supply line coupled to the second pull-up transistor. The method further includes applying a primary voltage from the first power supply line to the first pull-up transistor. The method also includes applying a secondary voltage from the second power supply line to the second pull-up transistor, wherein the secondary voltage is higher than the primary voltage. Further, the method includes performing a write operation to save a selected value in the memory cell.

Abstract: In described embodiments, a strength testing device that can be applied to a weight stack is provided. The strength testing device can be used in physical therapy, chiropractics, or other rehabilitation professionals to assess the strength of a patient. The strength testing device can also be used in the fitness industry by strength coaches and personal trainers.

Abstract: Semiconductor memory devices and methods for writing data in memory cells are provided. An exemplary method for writing data in a memory cell includes providing the memory cell with a first pull-up transistor, a first power supply line coupled to the first pull-up transistor, a second pull-up transistor, and a second power supply line coupled to the second pull-up transistor. The method further includes applying a primary voltage from the first power supply line to the first pull-up transistor. The method also includes applying a secondary voltage from the second power supply line to the second pull-up transistor, wherein the secondary voltage is higher than the primary voltage. Further, the method includes performing a write operation to save a selected value in the memory cell.

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Abstract: Disclosed herein are methods, compositions, and kits for treating a B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor. Also disclosed herein are methods, compositions, and kits for treating a BTK-resistant B-cell malignancy comprising administering a combination of a BTK inhibitor (e.g. ibrutinib) and a PIM inhibitor.